Synergy Pharmaceuticals (SGYP) Inactive 10-Q11 Aug 142014 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Aug. 11, 2014
Document and Entity Information	'	'
Entity Registrant Name	'SYNERGY PHARMACEUTICALS, INC.	'
Entity Central Index Key	'0001347613	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	94,795,019
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$1,200	$18,130
Available-for-sale securities	49,999	50,027
Prepaid expenses and other current assets	4,798	3,718
Total Current Assets	55,997	71,875
Property and equipment, net	589	589
Security deposits	163	94
Total Assets	56,749	72,558
Current Liabilities:	'	'
Accounts payable	12,223	13,542
Accrued expenses	5,713	2,134
Total Current Liabilities	17,936	15,676
Derivative financial instruments, at estimated fair value-warrants	555	1,534
Total Liabilities	18,491	17,210
Stockholders' Equity:	'	'
Preferred stock, Authorized 20,000,000 shares, at June 30, 2014 and December 31, 2013, none outstanding	'	'
Common stock, par value of $.0001 authorized 200,000,000 shares at June 30, 2014 and December 31, 2013. Issued and outstanding 94,109,263 and 90,182,115 shares at June 30, 2014 and December 31, 2013, respectively.	10	10
Additional paid-in capital	251,570	226,515
Accumulated deficit	-213,322	-171,177
Total Stockholders' Equity	38,258	55,348
Total Liabilities and Stockholders' Equity	$56,749	$72,558

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS	'	'
Preferred stock, authorized shares	20,000,000	20,000,000
Preferred stock, outstanding shares	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized shares	200,000,000	200,000,000
Common stock, Issued shares	94,109,263	90,182,115
Common stock, outstanding shares	94,109,263	90,182,115

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Costs and Expenses:	'	'	'	'
Research and development	$24,479	$9,055	$37,778	$23,399
General and administrative	2,279	2,803	5,457	6,081
Loss from Operations	-26,758	-11,858	-43,235	-29,480
Other Income/(Loss)	'	'	'	'
Interest and investment income -net	-1	16	28	34
State R&D tax credits	83	'	83	'
Change in fair value of derivative instruments-warrants	756	1,803	979	710
Total Other Income	838	1,819	1,090	744
Net Loss	($25,920)	($10,039)	($42,145)	($28,736)
Weighted Average Common Shares Outstanding	'	'	'	'
Basic and Diluted (in shares)	94,069,703	87,482,939	93,068,476	80,176,564
Net Loss per Common Share, Basic and Diluted	'	'	'	'
Net Loss per Common Share, Basic and Diluted (in dollars per share)	($0.28)	($0.11)	($0.45)	($0.36)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock, Par Value	Additional Paid in Capital	Accumulated Deficit	Non-Controlling interest
Balance at Dec. 31, 2013	$55,348,000	$10,000	$226,515,000	($171,177,000)	'
Balance (in shares) at Dec. 31, 2013	90,182,115	90,182,115	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement	22,795,000	'	22,795,000	'	'
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)	'	3,917,149	'	'	'
Fees and expenses related to controlled equity sales	-629,000	'	-629,000	'	'
Stock based compensation expense	2,264,000	'	2,264,000	'	'
Exercise of stock options	36,000	'	36,000	'	'
Exercise of stock options (in shares)	'	9,999	'	'	'
Private placement of ContraVir common stock	3,224,000	'	3,224,000	'	'
Fees and expenses associated with ContraVir Private Placement	-15,000	'	-15,000	'	'
Fair value of ContraVir warrants issued in connection with private placement	-880,000	'	-880,000	'	'
Noncontrolling interest of ContraVir	-1,622,000	'	'	'	-1,622,000
Distribution of ContraVir common stock to Synergy shareholders	-1,740,000	'	-1,740,000	'	'
Elimination of noncontrolling interest of ContraVir upon distribution	1,622,000	'	'	'	1,622,000
Net loss for the period	-42,145,000	'	'	-42,145,000	'
Balance at Jun. 30, 2014	$38,258,000	$10,000	$251,570,000	($213,322,000)	'
Balance (in shares) at Jun. 30, 2014	94,109,263	94,109,263	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash Flows From Operating Activities:	'	'
Net loss	($42,145)	($28,736)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	57	'
Stock-based compensation expense	2,264	2,168
Accretion of discount/premium on investment securities	28	98
Change in fair value of derivative instruments-warrants	-979	-710
Changes in operating assets and liabilities:	'	'
Security deposit	-69	'
Accounts payable and accrued expenses	2,421	-623
Prepaid expenses and other current assets	-1,086	-802
Total Adjustments	2,636	131
Net Cash Used in Operating Activities	-39,509	-28,605
Cash Flows From Investing Activities:	'	'
Loans to related parties	'	-270
Purchases of available-for-sale securities	'	-64,000
Additions to property and equipment	-57	-459
Repayment on ContraVir loan receivable	455	'
Net Cash Provided by /(Used in) Investing Activities	398	-64,729
Cash Flows From Financing Activities:	'	'
Issuance of common stock pursuant to controlled equity sales agreement	22,795	94,734
Issuance of common stock of ContraVir	3,224	'
Fees and expenses related to equity issuances	-644	-5,623
Proceeds from exercise of stock options	36	119
Distribution of cash associated with ContraVir Spinoff	-3,230	'
Net Cash Provided by Financing Activities	22,181	89,230
Net decrease in cash and cash equivalents	-16,930	-4,104
Cash and cash equivalents at beginning of period	18,130	12,416
Cash and cash equivalents at end of period	1,200	8,312
Supplementary disclosure of cash flow information:	'	'
Cash paid for taxes	30	27
Supplementary disclosure of non-cash investing and financing activities:	'	'
Value of warrants classified as derivative liability-net	'	-3,575
Recapitalization of Synergy	'	4,904
Distribution of net assets of ContraVir	$84	'

Business_Overview

Business Overview	6 Months Ended
Business Overview	Jun. 30, 2014
Business Overview	'
Business Overview	'
	1. Business Overview

	Synergy Pharmaceuticals (“Synergy” or the “Company”) is a biopharmaceutical company focused on the development of novel therapies based on the naturally occurring human hormone, uroguanylin, to treat GI diseases and disorders. Synergy has created two unique analogs of uroguanylin — plecanatide and SP-333 — designed to mimic the natural hormone’s activity on the intestinal guanylate cyclase-C (GC-C) receptor and target a variety of GI conditions. Plecanatide is currently in two pivotal phase 3 trials for chronic idiopathic constipation (CIC) and recently reached the halfway mark for patient enrollment in the first CIC registration trial. Synergy plans to release topline data from the first CIC registration trial in the second quarter of 2015. In April 2014, the Company announced positive top-line data results with plecanatide in a phase 2b study for irritable bowel syndrome with constipation (IBS-C). Synergy plans to initiate its pivotal phase 3 IBS-C program with plecanatide in the fourth quarter of this year.

	SP-333 is Synergy’s next-generation uroguanylin analog in development for the treatment of opioid-induced constipation (OIC) and mild-to-moderate ulcerative colitis. SP-333 is designed to be a highly potent and stable version of the naturally occurring gastrointestinal (GI) hormone, uroguanylin, and resistant to proteolysis in gastric intestinal fluids. SP-333 has completed phase 1 single and multiple ascending dose studies in healthy volunteers and is currently in a phase 2 clinical trial for OIC. Synergy is also developing a unique formulation of SP-333 for treating GI inflammation in patients with ulcerative colitis.

Basis_of_Presentation

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2014
Basis of Presentation	'
Basis of Presentation	'
	2. Basis of Presentation

	These unaudited condensed consolidated financial statements include Synergy and its wholly-owned subsidiaries: (1) Synergy Advanced Pharmaceuticals, Inc., (2) ContraVir Pharmaceuticals, Inc. (through February 14, 2014) and (3) IgX, Ltd (Ireland—inactive). These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and United States generally accepted accounting principles (“GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly Synergy’s interim financial information. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2013 contained in the Company’s Annual Report on Form 10-K filed with the Securities Exchange Commission (“SEC”) on March 17, 2014. All intercompany balances and transactions have been eliminated.

	On February 18, 2014, Synergy completed the distribution of ContraVir common stock (its previous wholly-owned subsidiary), to the Company’s stockholders on a pro rata basis with a stock dividend of .0986 ContraVir shares for each Synergy common stock share held as of the record date of February 6, 2014. Synergy accounted for this distribution according to FASB ASC Topic 505-60, Spinoffs and reverse spinoffs by eliminating ContraVir’s net assets of approximately $1.7 million, with a corresponding decrease in additional paid in capital and eliminating the non-controlling interest of $1.6 million. The spin-off of ContraVir’s operation had an immaterial effect on Synergy’s financial statements.

	These condensed consolidated financial statements as of June 30, 2014 have been prepared under the assumption that Synergy will continue as a going concern. Synergy’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate revenue. The condensed consolidated financial statements as of June 30, 2014 do not include any adjustments that might result from the outcome of this uncertainty.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
Recent Accounting Pronouncements	Jun. 30, 2014
Recent Accounting Pronouncements	'
Recent Accounting Pronouncements	'
	3. Recent Accounting Pronouncements

	On June 13, 2014, the FASB issued ASU 2014-101( “Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in ASC Topic 810, Consolidation”) to eliminate the concept of a development stage entity (“DSE”) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs and is intended to result in cost-savings for affected entities, such as certain start-up or research and development entities. In addition, ASU 2014-10 introduces new disclosure requirements about the reporting entity’s risks and uncertainties. ASU 2014-101 is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. Synergy elected early adoption as of June 30, 2014 and does not believe the adoption of the standard had a material impact on its financial position, results of operations or related financial statement disclosures.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
Fair Value of Financial Instruments	Jun. 30, 2014
Fair Value of Financial Instruments	'
Fair Value of Financial Instruments	'
	4. Fair Value of Financial Instruments

	Financial instruments consist of cash and cash equivalents, available-for-sale securities, accounts payable and derivative instruments. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short term nature, except available-for-sale securities and derivative instruments which are marked to market at the end of each reporting period. (footnote 5 and footnote 9)

Cash_Cash_Equivalents_and_Mark

Cash, Cash Equivalents and Marketable Securities	6 Months Ended
Cash, Cash Equivalents and Marketable Securities	Jun. 30, 2014
Cash, Cash Equivalents and Marketable Securities	'
Cash, Cash Equivalents and Marketable Securities	'
	5. Cash, Cash Equivalents and Marketable Securities

	All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. As of June 30, 2014, the amount of cash and cash equivalents was $1.2 million and consists of checking accounts and short-term money market funds held at U.S. commercial banks. As of December 31, 2013, the amount of cash and cash equivalents was approximately $18.1 million and consisted of checking accounts and short-term money market funds with U.S. commercial banks. At any point in time, the Company’s balance of cash and cash equivalents may exceed federally insured limits.

	The Company’s marketable securities as of June 30, 2014 and December 31, 2013 consist of approximately $50 million in U.S. Treasury securities with maturities of less than one year and have been classified and accounted for as available-for-sale. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the available-for-sale designations as of each balance sheet date. As of June 30, 2014, gross unrealized losses were not material. The Company recognized no net realized gains or losses for the three and six months ended June 30, 2014. The Company considers the declines in market value of its marketable securities investment portfolio to be temporary in nature. Fair values were determined for each individual security in the investment portfolio. When evaluating the investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, and the Company’s intent to sell, or whether it is more likely than not it will be required to sell, the investment before recovery of the investment’s amortized cost basis. During the three and six months ended June 30, 2014 and the year ended December 31, 2013, the Company did not recognize any impairment charges. As of June 30, 2014 and December 31, 2013, the Company did not consider any of its investments to be other-than-temporarily impaired.

Accounting_for_SharedBased_Pay

Accounting for Shared-Based Payments	6 Months Ended
Accounting for Shared-Based Payments	Jun. 30, 2014
Accounting for Shared-Based Payments	'
Accounting for Shared-Based Payments	'
	6. Accounting for Shared-Based Payments

	Stock Options

	ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. ASC Topic 718 did not change the way Synergy accounts for non-employee stock-based compensation. Synergy continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 “ Equity -Based Payment to Non-Employees” and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

	ASC Topic 718 requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities. Due to Synergy’s accumulated deficit position, no excess tax benefits have been recognized. Synergy accounts for common stock, stock options, and warrants granted to employees and non-employees based on the fair market value of the instrument, using the Black-Scholes option pricing model based on assumptions for expected stock price volatility, term of the option, risk-free interest rate and expected dividend yield, at the grant date.

	Synergy adopted the 2008 Equity Compensation Incentive Plan (the “Plan”) during the quarter ended September 30, 2008. Stock options granted under the Plan typically vest after three years of continuous service from the grant date and have a contractual term of ten years. On January 17, 2013, Synergy amended its 2008 Equity Compensation Incentive Plan and increased the number of shares of its common stock reserved for issuance under the Plan from 7,500,000 to 15,000,000.

	Stock-based compensation has been recognized in operating results as follow:

		Three Months						Six Months
		Ended June 30,						Ended June 30
	($ in thousands)	2014			2013			2014			2013
	Employees—included in research and development	$	438		$	278		$	864		$	555
	Employees—included in general and administrative	468			331			863			781
	Subtotal employee stock based compensation	906			609			1,727			1,336
	Non-employees—included in research and development	(3		)	2			4			137
	Non-employees—included in general and administrative	96			300			533			695
	Subtotal non-employee stock based compensation	93			302			537			832

	Total stock-based compensation expense	$	999		$	911		$	2,264		$	2,168

	The unrecognized compensation cost related to non-vested stock options outstanding at June 30, 2014, net of expected forfeitures, was approximately $9 million to be recognized over a weighted-average remaining vesting period of approximately 2.2 years. This unrecognized compensation cost does not include amounts related to 4,364,000 shares of stock options which vest upon a change of control.

	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the periods indicated.

		Six Months Ended		Six Months Ended
		June 30, 2014		June 30, 2013
	Risk-free interest rate	1.78%-1.98%		0.41%-1.11%
	Dividend yield	—		—
	Expected volatility	60%		60%
	Expected term (in years)	6 years		6 years

	A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:

		Number of		Exercise Price			Weighted Average			Intrinsic			Weighted Average
		Options		Per Share			Exercise Price			Value			Remaining
							Per Share			(in thousands)			Contractual Term
	Balance outstanding, December 31, 2013(1)	11,324,049		$	0.44-20.01		$	3.31		$	37,521		6.94 years
	Granted	1,659,000		$	4.24-5.97		$	4.63
	Exercised	(9,999	)	$	3.40-3.95		$	3.58		$	23
	Forfeited	(110,190	)	$	8.34-20.01		$	17.51

	Balance outstanding, June 30, 2014(1)	12,862,860		$	0.44-13.90		$	3.36		$	14,692		6.94 years
	Exercisable, at June 30, 2014	5,227,566		$	0.44-13.90		$	2.82		$	8,238		5.81 years

	(1) Number of options represented above includes 4,360,000 options vesting upon change of control, granted during the years ended December 31, 2009 and 2010, at an exercise price of $0.70 per share. Because the probability of a change of control transaction is not predictable no stock based compensation expense associated with these options has been recognized since the grant date.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
Stockholders' Equity	'
	7. Stockholders’ Equity

	On March 5, 2014, Synergy entered into Amendment No. 1 (the “Amendment”) to its Controlled Equity Offering Sales Agreement, dated June 21, 2012 (as amended, the “Agreement”), with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which the Company may offer and sell, from time to time, through Cantor shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), up to an additional aggregate offering price of $50.0 million. The Company intends to use the net proceeds of this offering to fund its research and development activities, including further clinical development of plecanatide and SP-333, and for working capital and other general corporate purposes, and possible acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

	Under the Agreement, Cantor may sell the Shares by methods deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on The NASDAQ Global Select Market, on any other existing trading market for the Shares or to or through a market maker. In addition, under the Agreement, Cantor may sell the Shares by any other method permitted by law, including in privately negotiated transactions. Subject to the terms and conditions of the Agreement, Cantor will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The NASDAQ Global Select Market, to sell the Shares from time to time, based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose).

	Synergy is not obligated to make any sales of the Shares under the Agreement. The offering of Shares pursuant to the Agreement will terminate upon the earlier of (1) the sale of all of the Shares subject to the Agreement or (2) the termination of the Agreement by Cantor or the Company. The Company will pay Cantor a commission of up to 3.0% of the gross sales price per share sold and has agreed to provide Cantor with customary indemnification and contribution rights.

	Pursuant to the original Agreement, Synergy sold 3,644,143 shares of common stock, from January 1, 2014 through March 4, 2014, yielding gross proceeds of approximately $21.2 million, at an average selling price of $5.82 per share. This completed the $30 million of proposed sales of common stock pursuant to the Agreement. Under the Amendment, Synergy sold an additional 273,006 shares of common stock, from March 5, 2014 through June 30, 2014, yielding gross proceeds of $1.6 million, at an average selling price of $5.78 per share. Selling agent fees related to above financings from January 1, 2014 through June 30, 2014 were approximately $629,000.

	Proceeds from exercise of stock options were $36,000 from January 1, 2014 through June 30, 2014.

	ContraVir

	Private Placement

	On February 4, 2014, Synergy’s wholly owned subsidiary, ContraVir Pharmaceuticals, Inc. (ContraVir) entered into a securities purchase agreement with accredited investors to sell securities and raise gross proceeds of approximately $3.2 million in a private placement and incurred expenses of $15,000 related to this placement. ContraVir sold 9,485,294 units to the investors with each unit consisting of one share of ContraVir’s common stock and one warrant to purchase an additional one half share of ContraVir’s common stock. The purchase price paid by the investors was $0.34 for each unit. The 4.7 million warrants expire after six years and are exercisable at $0.37 per share. Based upon the ContraVir’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity” ContraVir recorded approximately $0.88 million of derivative liability on the warrants issued in connection with this transaction.

	Spin-off

	On February 18, 2014, Synergy completed the distribution of the ContraVir common stock (its previous wholly-owned subsidiary) to Synergy’s stockholders on a pro rata basis with a stock dividend of .0986 ContraVir shares for each Synergy common stock share held as of the record date of February 6, 2014.

	Synergy accounted for this distribution according to FASB ASC Topic 505-60, Spinoffs and reverse spinoffs by eliminating ContraVir’s net assets of approximately $1.7 million, with a corresponding decrease in additional paid in capital and the non-controlling interest of $1.6 million.

	Net assets of ContraVir eliminated in connection with this spin-off was as follows:

		Balance
	($ in thousands)	February 18, 2014
		(unaudited)
	Assets
	Cash	$	3,230
	Prepaid expense	6
	Total assets	3,236
	Accounts payable and other liabilities	(107		)
	Note Payable to Synergy	(455		)
	Due to Synergy	(54		)
	Derivative financial instruments, at estimated fair value-warrants	(880		)

	Total Liabilities	(1,496		)
	Net assets	$	1,740

	As a result of the ContraVir distribution, an adjustment was made to the exercise price of all outstanding Synergy warrants in accordance with their terms. Accordingly the exercise price decreased approximately $0.011 per share on the record date. As of June 30, 2014, there were 5,647,203 Synergy non-public warrants outstanding with a weighted average exercise price of $5.37 per share pre-distribution and $5.359 per share as adjusted. The spin-off of ContraVir’s operation had an immaterial effect on Synergy’s financial statements.

	Loan and Security Agreement

	On June 5, 2013, ContraVir entered into a Loan and Security Agreement with Synergy pursuant to which Synergy agreed to lend ContraVir up to five hundred thousand dollars ($500,000) for working capital purposes (the “Loan Agreement”). Also on June 5, 2013, August 29, 2013, October 18, 2013 and January 9, 2014, pursuant to the Loan Agreement, Synergy made an advance to ContraVir of $100,000, $100,000, $150,000 and $100,000, respectively, under a promissory note (the “Note”). The Note bears interest at six percent (6%) per annum. In connection with the Loan Agreement ContraVir granted Synergy a security interest in all of its assets, including its intellectual property, until the Note is repaid in full. On November 18, 2013, ContraVir entered into an amendment to the Loan Agreement with Synergy pursuant to which Synergy agreed to increase the aggregate amount available to ContraVir under the Loan Agreement from five hundred thousand dollars ($500,000) to one million dollars ($1,000,000). On March 27, 2014, ContraVir paid $461,236 to Synergy in full repayment of the advance, including accrued but unpaid interest thereon.

	Shared Services Agreement

	On July 8, 2013, ContraVir entered into a Shared Services Agreement, as amended and restated August 5, 2013, with Synergy, effective May 16, 2013. Under the Shared Services Agreement, Synergy has provided and/or made available to ContraVir various administrative, financial (accounting), insurance, facility, information technology, and other services. In consideration for such services, ContraVir paid fees to Synergy sufficient to allow Synergy to recover all of its direct and indirect costs incurred in providing those services. Effective April 1, 2014, Synergy terminated the shared services agreement with ContraVir.

Research_and_Development_Expen

Research and Development Expense	6 Months Ended
Research and Development Expense	Jun. 30, 2014
Research and Development Expense	'
Research and Development Expense	'
	8. Research and Development Expense

	Research and development costs include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research, patient costs, drug formulation and tableting, data collection, monitoring, and clinical insurance.

	In accordance with FASB ASC Topic 730-10-55, Research and Development, Synergy recorded prepaid research and development costs of approximately $4.4 million and $3.6 million as of June 30, 2014 and December 31, 2013, respectively, for nonrefundable pre-payments for production of drug substance and analytical testing services for its drug candidates. In accordance with this guidance, Synergy expenses these costs when drug compound is delivered and services are performed.

Derivative_Financial_Instrumen

Derivative Financial Instruments

6 Months Ended

Jun. 30, 2014

Derivative Financial Instruments

9. Derivative Financial Instruments

Synergy Derivative Financial Instruments

Effective January 1, 2009, the Company adopted provisions of ASC Topic 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity” (“ASC Topic 815-40”). ASC Topic 815-40 clarifies the determination of whether an instrument issued by an entity (or an embedded feature in the instrument) is indexed to an entity’s own stock, which would qualify as a scope exception under ASC Topic 815-10.

Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Synergy has determined that certain warrants issued in connection with sale of its common stock must be classified as derivative instruments. In accordance with ASC Topic 815-40, these warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value is being recorded in the Company’s statement of operations. The Company estimates the fair value of certain warrants using the Black-Scholes option pricing model in order to determine the associated derivative instrument liability and change in fair value described above. The range of assumptions used to determine the fair value of the warrants at each period end were:

Six Months Ended

June 30, 2014

June 30, 2013

Fair value of Synergy common stock

4.07

4.23

Expected warrant term

1.0 — 3.7 years

2 — 4.7 years

Risk-free interest rate

0.11%-1.32%

0.36% - 1.41%

Expected volatility

60%

Dividend yield

—

Fair value of stock is the closing market price of the Company’s common stock on the date of warrant issuance and at the end of each reporting period when the derivative instruments are marked to market. Expected volatility is a management estimate of future volatility, over the expected warrant term, based on historical volatility of Synergy’s common stock. The warrants have a transferability provision and based on guidance provided in SAB 107 for instruments issued with such a provision, Synergy used the full contractual term as the expected term of the warrants. The risk free rate is based on the U.S. Treasury security rates for maturities consistent with the expected remaining term of the warrants at the date of grant or quarterly revaluation.

The following table sets forth the components of changes in the Synergy’s outstanding warrants which were deemed derivative financial instruments and the associated liability balance for the periods indicated:

Date

Description

Warrants

Derivative

Instrument

Liability

($ in thousands)

12/31/12

Balance of derivative financial instruments liability

2,265,160

5,258

3/31/13

Change in fair value of warrants during the quarter

—

1,093

3/31/13

Balance of derivative financial instruments liability

2,265,160

6,351

6/30/13

Fair value of new warrants issued during the quarter

—

6/30/13

Reclassification of derivative liability to equity during the quarter

(1,406,691

)

(3,575

)

6/30/13

Change in fair value of warrants during the quarter

—

(1,803

)

6/30/13

Balance of derivative financial instruments liability

858,469

973

9/30/13

Fair value of new warrants issued during the quarter

—

9/30/13

Change in fair value of warrants during the quarter

—

9/30/13

Balance of derivative financial instruments liability

858,469

1,050

12/31/13

Fair value of new warrants issued during the quarter

—

12/31/13

Change in fair value of warrants during the quarter

—

484

12/31/13

Balance of derivative financial instruments liability

858,469

1,534

3/31/14

Fair value of new warrants issued during the quarter

—

3/31/14

Change in fair value of warrants during the quarter

—

(223

)

3/31/14

Balance of derivative financial instruments liability

858,469

1,311

6/30/14

Fair value of new warrants issued during the quarter

—

6/30/14

Change in fair value of warrants during the quarter

—

6/30/14

Balance of derivative financial instruments liability

(756

)

858,469

555

Synergy Fair Value Measurements

The following table presents the Company’s liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2013 and June 30, 2014:

($ in thousands)

Description

Quoted Prices

Significant

Balance as of

Quoted Prices

Significant

Balance as of

Other

Unobservable

December 31,

Other

Unobservable

June 30,

Active

Observable

Inputs

2013

Active

Observable

Inputs

2014

Markets

Inputs

(Level 3)

Markets

Inputs

(Level 3)

for Identical

(Level 2)

for Identical

(Level 2)

Assets and

Liabilities

(Level 1)

Derivative liabilities related to Warrants

—

1,534

—

555

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2014:

Description

Balance at

Fair Value of

(Gain) or loss

Balance as of

December 31,

warrants upon

recognized in

June 30,

2013

issuance

earning from

2014

Change in Fair

Value

Derivative liabilities related to Warrants

1,534

—

(979

)

555

The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company’s statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, Synergy reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

On January 28, 2014, the Synergy Board of Directors declared a stock dividend of .0986 ContraVir shares for each share of Synergy common stock held as of the record date of February 6, 2014, which was distributed on February 18, 2014. As a result of the distribution, an adjustment was made to the exercise price of all outstanding warrants in accordance with their terms and accordingly the exercise price decreased approximately $0.011 per share on the record date and was reflected in the fair value calculation of the warrants. As of the record date there were 5,647,203 warrants outstanding with a weighted average exercise price of $5.37 per share pre-distribution and $5.359 per share as adjusted.

Loss_per_Share

Loss per Share	6 Months Ended
Loss per Share	Jun. 30, 2014
Loss per Share	'
Loss per Share	'
	10. Loss per Share

	Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC Topic 260”) for periods presented. In accordance with ASC Topic 260, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Diluted weighted-average shares are the same as basic weighted-average shares because shares issuable pursuant to the exercise of stock options would be antidilutive. For the three and six months ended June 30, 2014 and June 30, 2013 the effect of 12,862,860 and 10,463,063, respectively outstanding stock options, at the end of each period, were excluded from the calculation of diluted loss per share because the effect was antidilutive. For the three and six months ended June 30, 2014 and June 30, 2013, the effect of 5,647,203 outstanding warrants were excluded from the calculation of diluted loss per share because the effect was antidilutive.

Subsequent_Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2014
Subsequent Events	'
Subsequent Events	'
	11. Subsequent Events

	From July 1, 2014 through August 10, 2014, Synergy sold an additional 685,781 shares of common stock, under Synergy’s Amended Controlled Equity Offering Sales Agreement with Cantor (footnote 7). These sales yielded gross proceeds of $2.8 million, at an average selling price of $4.10 per share. There is $45.6 million of common stock available unsold under the Amended Controlled Equity Offering Sales Agreement as of August 10, 2014.

Accounting_for_SharedBased_Pay1

Accounting for Shared-Based Payments (Tables)	6 Months Ended
Accounting for Shared-Based Payments (Tables)	Jun. 30, 2014
Accounting for Shared-Based Payments	'
Schedule of stock-based compensation expense	'


		Three Months						Six Months
		Ended June 30,						Ended June 30
	($ in thousands)	2014			2013			2014			2013
	Employees—included in research and development	$	438		$	278		$	864		$	555
	Employees—included in general and administrative	468			331			863			781
	Subtotal employee stock based compensation	906			609			1,727			1,336
	Non-employees—included in research and development	(3		)	2			4			137
	Non-employees—included in general and administrative	96			300			533			695
	Subtotal non-employee stock based compensation	93			302			537			832

	Total stock-based compensation expense	$	999		$	911		$	2,264		$	2,168
Schedule of weighted-average assumptions used to estimate fair value of stock option awards using the Black-Scholes option valuation model	'


		Six Months Ended		Six Months Ended
		June 30, 2014		June 30, 2013
	Risk-free interest rate	1.78%-1.98%		0.41%-1.11%
	Dividend yield	—		—
	Expected volatility	60%		60%
	Expected term (in years)	6 years		6 years
Summary of stock option activity and of changes in stock options outstanding under the Plan	'


		Number of		Exercise Price			Weighted Average			Intrinsic			Weighted Average
		Options		Per Share			Exercise Price			Value			Remaining
							Per Share			(in thousands)			Contractual Term
	Balance outstanding, December 31, 2013(1)	11,324,049		$	0.44-20.01		$	3.31		$	37,521		6.94 years
	Granted	1,659,000		$	4.24-5.97		$	4.63
	Exercised	(9,999	)	$	3.40-3.95		$	3.58		$	23
	Forfeited	(110,190	)	$	8.34-20.01		$	17.51

	Balance outstanding, June 30, 2014(1)	12,862,860		$	0.44-13.90		$	3.36		$	14,692		6.94 years
	Exercisable, at June 30, 2014	5,227,566		$	0.44-13.90		$	2.82		$	8,238		5.81 years

	(1) Number of options represented above includes 4,360,000 options vesting upon change of control, granted during the years ended December 31, 2009 and 2010, at an exercise price of $0.70 per share. Because the probability of a change of control transaction is not predictable no stock based compensation expense associated with these options has been recognized since the grant date.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
Schedule of net assets of ContraVir eliminated in connection with the spin-off	'


		Balance
	($ in thousands)	February 18, 2014
		(unaudited)
	Assets
	Cash	$	3,230
	Prepaid expense	6
	Total assets	3,236
	Accounts payable and other liabilities	(107		)
	Note Payable to Synergy	(455		)
	Due to Synergy	(54		)
	Derivative financial instruments, at estimated fair value-warrants	(880		)

	Total Liabilities	(1,496		)
	Net assets	$	1,740

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	6 Months Ended
Derivative Financial Instruments (Tables)	Jun. 30, 2014
Derivative Financial Instruments	'
Schedule of range of assumptions used to determine the fair value of the warrants	'


		Six Months Ended			Six Months Ended
		June 30, 2014			June 30, 2013
	Fair value of Synergy common stock	$	4.07		$	4.23
	Expected warrant term	1.0 — 3.7 years			2 — 4.7 years
	Risk-free interest rate	0.11%-1.32%			0.36% - 1.41%
	Expected volatility	60%			60%
	Dividend yield	—			—
Schedule of changes in derivative financial instruments and associated liability balance	'


	Date	Description		Warrants		Derivative
						Instrument
						Liability
						($ in thousands)
	12/31/12	Balance of derivative financial instruments liability		2,265,160		$	5,258

	3/31/13	Change in fair value of warrants during the quarter		—		1,093

	3/31/13	Balance of derivative financial instruments liability		2,265,160		6,351
	6/30/13	Fair value of new warrants issued during the quarter		—		—
	6/30/13	Reclassification of derivative liability to equity during the quarter		(1,406,691	)	(3,575		)
	6/30/13	Change in fair value of warrants during the quarter		—		(1,803		)
	6/30/13	Balance of derivative financial instruments liability		858,469		973
	9/30/13	Fair value of new warrants issued during the quarter		—		—
	9/30/13	Change in fair value of warrants during the quarter		—		77

	9/30/13	Balance of derivative financial instruments liability		858,469		1,050
	12/31/13	Fair value of new warrants issued during the quarter		—		—
	12/31/13	Change in fair value of warrants during the quarter		—		484

	12/31/13	Balance of derivative financial instruments liability		858,469		1,534
	3/31/14	Fair value of new warrants issued during the quarter		—		—
	3/31/14	Change in fair value of warrants during the quarter		—		(223		)
	3/31/14	Balance of derivative financial instruments liability		858,469		$	1,311
	6/30/14	Fair value of new warrants issued during the quarter		—		—
	6/30/14	Change in fair value of warrants during the quarter		—
	6/30/14	Balance of derivative financial instruments liability				(756		)
				858,469		$	555
Schedule of liabilities that are measured and recognized at fair value on a recurring basis	'


	($ in thousands)

	Description	Quoted Prices			Significant			Significant			Balance as of		Quoted Prices		Significant		Significant		Balance as of
		in			Other			Unobservable			December 31,		in		Other		Unobservable		June 30,
		Active			Observable			Inputs			2013		Active		Observable		Inputs		2014
		Markets			Inputs			(Level 3)					Markets		Inputs		(Level 3)
		for Identical			(Level 2)								for Identical		(Level 2)
		Assets and											Assets and
		Liabilities											Liabilities
		(Level 1)											(Level 1)
	Derivative liabilities related to Warrants	$	—		$	—		$	1,534		$	1,534	$	—	$	—	$	555	$	555

Summary of changes in the fair value of Level 3 liabilities	'


	Description	Balance at			Fair Value of			(Gain) or loss			Balance as of
		December 31,			warrants upon			recognized in			June 30,
		2013			issuance			earning from			2014
								Change in Fair
								Value
	Derivative liabilities related to Warrants	$	1,534		$	—		$	(979	)	$	555

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	6 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Feb. 18, 2014	Feb. 18, 2014	Feb. 18, 2014
		Spin-off	ContraVir	ContraVir
		ContraVir Subsidiary		Spin-off
Basis of presentation	'	'	'	'
ContraVir shares distributed for each Synergy common stock share held	'	'	0.0986	'
Net assets	'	$1,740	'	'
Elimination of noncontrolling interest of ContraVir upon distribution	$1,622	'	'	$1,600

Cash_Cash_Equivalents_and_Mark1

Cash, Cash Equivalents and Marketable Securities (Details) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Cash, Cash Equivalents and Marketable Securities	'	'	'	'	'
Cash and cash equivalents	$1,200,000	$1,200,000	$18,130,000	$8,312,000	$12,416,000
Available-for-sale securities	49,999,000	49,999,000	50,027,000	'	'
Net realized gains or losses	$0	$0	'	'	'

Accounting_for_SharedBased_Pay2

Accounting for Shared-Based Payments (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jan. 17, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

2008 Equity Compensation Incentive Plan

Employees

Non-employees

Stock options

Research and development

General and administrative

Research and development

General and administrative

Shared-based payments

Amount of excess tax benefits recognized (in dollars)

Vesting period

'3 years

Contractual term

'10 years

Number of shares reserved under the plan

15,000,000

7,500,000

Total stock-based compensation expense (in dollars)

999,000

911,000

2,264,000

2,168,000

906,000

609,000

1,727,000

1,336,000

438,000

278,000

864,000

555,000

468,000

331,000

863,000

781,000

93,000

302,000

537,000

832,000

-3,000

2,000

4,000

137,000

96,000

300,000

533,000

695,000

Unrecognized compensation cost related to non-vested employee stock options, net of expected forfeitures (in dollars)

$9,000,000

Weighted-average remaining vesting period over which unrecognized compensation cost is to be recognized

'2 years 2 months 12 days

Number of stock options which vest upon a change of control (in shares)

4,364,000

Weighted-average assumptions used to estimate fair value of stock option awards using the Black-Scholes option valuation model

Risk-free interest rate, minimum (as a percent)

1.78%

0.41%

Risk-free interest rate, maximum (as a percent)

1.98%

1.11%

Expected volatility (as a percent)

60.00%

Expected term

'6 years

Accounting_for_SharedBased_Pay3

Accounting for Shared-Based Payments (Details 2) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended	60 Months Ended	6 Months Ended				66 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
					Stock options	Stock options	Stock options	Stock options	Stock options	Stock options	Stock options
					Exercise price per Share 0.44 - 20.01	Exercise price per Share 0.44 - 20.01	Exercise price per share 4.24 - 5.97	Exercise price per share 3.40 - 3.95	Exercise price per share 8.34 - 20.01	Exercise price per share 0.44 - 13.90	Exercise price per share 0.44 - 13.90
						Contingent vesting					Contingent vesting
Number of Options	'	'	'	'	'	'	'	'	'	'	'
Granted (in shares)	'	'	'	'	'	'	1,659,000	'	'	'	'
Exercised (in shares)	'	'	'	'	'	'	'	-9,999	'	'	'
Forfeited (in shares)	'	'	'	'	'	'	'	'	-110,190	'	'
Balance outstanding, end of period (in shares)	'	'	'	'	11,324,049	4,360,000	'	'	'	12,862,860	4,360,000
Exercisable at the end of the period (in shares)	'	'	'	'	'	'	'	'	'	5,227,566	'
Exercise Price Per Share	'	'	'	'	'	'	'	'	'	'	'
Exercise price, low end of the range (in dollars per share)	'	'	'	'	$0.44	'	$4.24	$3.40	$8.34	$0.44	'
Exercise price, high end of the range (in dollars per share)	'	'	'	'	$20.01	'	$5.97	$3.95	$20.01	$13.90	'
Weighted Average Exercise Price Per Share	'	'	'	'	'	'	'	'	'	'	'
Granted (in dollars per share)	'	'	'	'	'	'	$4.63	'	'	'	'
Exercised (in dollars per share)	'	'	'	'	'	'	'	$3.58	'	'	'
Forfeited (in dollars per share)	'	'	'	'	'	'	'	'	$17.51	'	'
Balance outstanding, end of period (in dollars per share)	'	'	'	'	$3.31	$0.70	'	'	'	$3.36	$0.70
Exercisable at the end of the period (in dollars per share)	'	'	'	'	'	'	'	'	'	$2.82	'
Intrinsic Value	'	'	'	'	'	'	'	'	'	'	'
Intrinsic value of options outstanding (in dollars)	'	'	'	'	$37,521,000	'	'	'	'	$14,692,000	'
Intrinsic value of options exercised (in dollars)	'	'	'	'	'	'	'	23,000	'	'	'
Intrinsic value of options exercisable (in dollars)	'	'	'	'	'	'	'	'	'	8,238,000	'
Weighted Average Remaining Contractual Term	'	'	'	'	'	'	'	'	'	'	'
Balance at the end of the period	'	'	'	'	'6 years 11 months 8 days	'	'	'	'	'6 years 11 months 8 days	'
Exercisable at the end of the period	'	'	'	'	'	'	'	'	'	'5 years 9 months 22 days	'
Additional disclosures	'	'	'	'	'	'	'	'	'	'	'
Total stock-based compensation expense (in dollars)	$999,000	$911,000	$2,264,000	$2,168,000	'	$0	'	'	'	'	$0

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	6 Months Ended				0 Months Ended	2 Months Ended	4 Months Ended	6 Months Ended	0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Mar. 05, 2014	Dec. 31, 2013	Mar. 05, 2014	Mar. 04, 2014	Jun. 30, 2014	Jun. 30, 2014	Mar. 05, 2014
					June 2012 Controlled Equity Offering Sales Agreement	June 2012 Controlled Equity Offering Sales Agreement	June 2012 Controlled Equity Offering Sales Agreement	June 2012 Controlled Equity Offering Sales Agreement	June 2012 Controlled Equity Offering Sales Agreement
									Maximum
Stockholders' equity	'	'	'	'	'	'	'	'	'
Common stock, par value (in dollars per share)	$0.00	'	$0.00	$0.00	'	'	'	'	'
Additional aggregate offering price of common stock	'	'	'	'	$50,000,000	'	'	'	'
Commission payable to Cantor as a percentage of gross sales price per share sold	'	'	'	'	'	'	'	'	3.00%
Common stock sold by the entity (in shares)	'	'	'	'	'	3,644,143	273,006	'	'
Gross proceeds from sale of common stock by the entity	22,795,000	94,734,000	'	'	'	21,200,000	1,578,260	'	'
Common stock, average selling price (in dollars per share)	'	'	'	'	'	$5.82	$5.78	'	'
Maximum share amount to be issued and sold under agreement	'	'	'	'	'	30,000,000	'	'	'
Selling agent fees	629,000	'	'	'	'	'	'	629,000	'
Proceeds from exercise of stock options	$36,000	$119,000	'	'	'	'	'	'	'

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)

0 Months Ended

6 Months Ended

0 Months Ended

Feb. 06, 2014

Jun. 30, 2014

Dec. 31, 2013

Feb. 18, 2014

Dec. 31, 2013

Feb. 18, 2014

Feb. 04, 2014

Feb. 18, 2014

Mar. 27, 2014

Jan. 09, 2014

Oct. 18, 2013

Aug. 29, 2013

Jun. 05, 2013

Nov. 18, 2013

Weighted average

ContraVir

February 4, 2014 Private Placement

ContraVir

Spin-off

ContraVir

Spin-off

Loan Agreement

Warrants

Stockholders' equity

Gross proceeds

$3,224,000

$3,200,000

Expenses related to private placement

15,000

Number of units sold (in shares)

9,485,294

Number of shares of common stock per unit

Number of warrants per unit (in shares)

Number of common shares that can be acquired upon exercise of each warrant

0.5

Purchase price (in dollars per unit)

$0.34

Expiration period of warrant

'6 years

Exercise price (in dollars per unit)

$5.36

$5.37

$0.37

Derivative liabilities related to Warrants

555,000

1,534,000

880,000

Shares of subsidiary distributed for each share of the entity's shares outstanding

0.0986

Assets

Cash

3,230,000

Prepaid expense

6,000

Total assets

3,236,000

Liabilities

Accounts payable and other liabilities

-107,000

Note Payable to Synergy

-455,000

Due to Synergy

-54,000

Derivative financial instruments, at estimated fair value-warrants

-880,000

Total Liabilities

-1,496,000

Net assets

1,740,000

Decrease in non-controlling interest

1,622,000

1,600,000

Decrease in exercise price (in dollars per share)

$0.01

Non-public warrants outstanding (in shares)

5,647,203

4,700,000

Maximum amount the entity agreed to lend

500,000

1,000,000

Amount of advance to subsidiary

100,000

150,000

100,000

Interest rate (as a percent)

6.00%

Repayment of advance by ContraVir

$461,236

Research_and_Development_Expen1

Research and Development Expense (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Research and Development Expense	'	'
Prepaid research and development costs	$4.40	$3.60

Derivative_Financial_Instrumen2

Derivative Financial Instruments (Details) (Derivative instrument liability, Warrants, Black-Scholes option pricing model, USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Range of assumptions used to determine the fair value of the warrants	'	'
Fair value of Synergy common stock (in dollars per share)	$4.07	$4.23
Expected volatility (as a percent)	60.00%	60.00%
Minimum	'	'
Range of assumptions used to determine the fair value of the warrants	'	'
Expected warrant term	'1 year	'2 years
Risk-free interest rate (as a percent)	0.11%	0.36%
Maximum	'	'
Range of assumptions used to determine the fair value of the warrants	'	'
Expected warrant term	'3 years 8 months 12 days	'4 years 8 months 12 days
Risk-free interest rate (as a percent)	1.32%	1.41%

Derivative_Financial_Instrumen3

Derivative Financial Instruments (Details 2) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Feb. 06, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
						Derivative instrument liability	Derivative instrument liability	Derivative instrument liability	Derivative instrument liability	Derivative instrument liability	Derivative instrument liability
						Warrants	Warrants	Warrants	Warrants	Warrants	Warrants
Changes in warrants	'	'	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period (in shares)	'	'	'	'	5,647,203	858,469	858,469	858,469	858,469	2,265,160	2,265,160
Reclassification of derivative liability to equity during the quarter (in shares)	'	'	'	'	'	'	'	'	'	-1,406,691	'
Balance at the end of the period (in shares)	5,647,203	'	5,647,203	'	5,647,203	858,469	858,469	858,469	858,469	858,469	2,265,160
Changes in derivative instrument liability	'	'	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period	'	'	$1,534	'	'	$1,311	$1,534	$1,050	$973	$6,351	$5,258
Reclassification of derivative liability to equity during the quarter	'	'	'	'	'	'	'	'	'	-3,575	'
Change in fair value of warrants during the quarter	-756	-1,803	-979	-710	'	-756	-223	484	77	-1,803	1,093
Balance at the end of the period	$555	'	$555	'	'	$555	$1,311	$1,534	$1,050	$973	$6,351

Derivative_Financial_Instrumen4

Derivative Financial Instruments (Details 3) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
Fair value measurements	'	'	'	'	'	'	'
Derivative liabilities related to Warrants	$555	'	$1,534	'	'	'	'
Derivative instrument liability \| Warrants	'	'	'	'	'	'	'
Fair value measurements	'	'	'	'	'	'	'
Derivative liabilities related to Warrants	555	1,311	1,534	1,050	973	6,351	5,258
Fair value on a recurring basis \| Significant Unobservable Inputs (Level 3) \| Derivative instrument liability \| Warrants	'	'	'	'	'	'	'
Fair value measurements	'	'	'	'	'	'	'
Derivative liabilities related to Warrants	555	'	1,534	'	'	'	'
Fair value on a recurring basis \| Total Fair Value \| Derivative instrument liability \| Warrants	'	'	'	'	'	'	'
Fair value measurements	'	'	'	'	'	'	'
Derivative liabilities related to Warrants	$555	'	$1,534	'	'	'	'

Derivative_Financial_Instrumen5

Derivative Financial Instruments (Details 4) (Derivative instrument liability, Warrants, Level 3, USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Derivative instrument liability \| Warrants \| Level 3	'
Changes in the fair value of Level 3 liabilities	'
Balance at the beginning of the period	$1,534
(Gain) or loss recognized in earning from Change in Fair Value	-979
Balance at the end of the period	$555

Derivative_Financial_Instrumen6

Derivative Financial Instruments (Details 5) (USD $)	0 Months Ended				0 Months Ended
	Feb. 06, 2014	Jun. 30, 2014	Feb. 18, 2014	Dec. 31, 2013	Feb. 18, 2014	Jan. 28, 2014
	Feb. 06, 2014	Jun. 30, 2014	Weighted average	Weighted average	ContraVir Subsidiary	ContraVir Subsidiary
Derivative Financial Instruments	'	'	'	'	'	'
Shares of subsidiary to be distributed for each share of the entity's shares outstanding	'	'	'	'	'	0.0986
ContraVir shares distributed for each Synergy common stock share held	'	'	'	'	0.0986	'
Decrease in exercise price (in dollars per share)	$0.01	'	'	'	'	'
Warrants outstanding (in shares)	5,647,203	5,647,203	'	'	'	'
Exercise price of warrants (in dollars per share)	'	'	$5.36	$5.37	'	'

Loss_per_Share_Details

Loss per Share (Details)	3 Months Ended		6 Months Ended
Loss per Share (Details)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock options	'	'	'	'
Loss per Share	'	'	'	'
Number of antidilutive securities excluded from the calculation of diluted loss per share (in shares)	12,862,860	10,463,063	12,862,860	10,463,063
Warrants	'	'	'	'
Loss per Share	'	'	'	'
Number of antidilutive securities excluded from the calculation of diluted loss per share (in shares)	5,647,203	5,647,203	5,647,203	5,647,203

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	6 Months Ended		2 Months Ended	4 Months Ended	1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Mar. 04, 2014	Jun. 30, 2014	Aug. 10, 2014
			June 2012 Controlled Equity Offering Sales Agreement	June 2012 Controlled Equity Offering Sales Agreement	Subsequent Event
					June 2012 Controlled Equity Offering Sales Agreement
Subsequent events	'	'	'	'	'
Common stock sold by the entity (in shares)	'	'	3,644,143	273,006	685,781
Gross proceeds from sale of common stock by the entity	$22,795,000	$94,734,000	$21,200,000	$1,578,260	$2,800,000
Common stock, average selling price (in dollars per share)	'	'	$5.82	$5.78	$4.10
Amount of common stock available for sale under agreement	'	'	'	'	$45,600,000